FLUORESCENT IN SITU HYBRIDISATION POSITIVE

FLUORESCENT IN SITU HYBRIDISATION POSITIVE was reported 10 times

FLUORESCENT IN SITU HYBRIDISATION POSITIVE is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Provitamin D2 Compound [EPC] 1 0.0000
1 Microtubule Inhibitor [EPC] 3 0.0000
2 Topoisomerase Inhibitor [EPC] 1 0.0000
3 Integrin Receptor Antagonist [EPC] 1 0.0000
4 Platinum-based Drug [EPC] 3 0.0000
5 Interleukin-12 Antagonist [EPC] 1 0.0000
6 Interleukin-23 Antagonist [EPC] 1 0.0000
7 Fluoroquinolone Antibacterial [EPC] 1 0.0000
8 Nucleoside Metabolic Inhibitor [EPC] 2 0.0000
9 Alkylating Drug [EPC] 1 0.0000
10 Thalidomide Analog [EPC] 1 0.0000
11 Proton Pump Inhibitor [EPC] 1 0.0000
12 Corticosteroid [EPC] 2 0.0000
13 Tumor Necrosis Factor Blocker [EPC] 1 0.0000